(Press-News.org) New research into the fight against Dengue, an insect-borne tropical disease that infects up to 390 million people worldwide annually, may influence the development of anti-viral therapies that are effective against all four types of the virus.
The findings, led by researchers at the University of Bristol and published in the Journal of Biological Chemistry today [2 August], show for the first time that there may be significant differences in specific properties of the viral proteins for the four dengue virus types.
Due to the effects of globalisation, including increased travel and urbanisation of human populations and the expanded geographical distribution of the mosquito vector that is responsible for the transmission of viral infections to millions of people, the number of individuals afflicted with dengue is rising.
Infection with any one of the four types of dengue virus (DENV types 1 - 4) may result in a spectrum of illnesses ranging from dengue fever, a mild flu like illness which causes high fever and joint pains, to the potentially fatal dengue haemorrhagic fever. Despite intensive research, dengue disease is not wholly understood, and there are no vaccines or anti-viral treatments available that can safely or effectively control the disease.
Dr Andrew Davidson, Senior Virologist and lead researcher from the University of Bristol, and colleagues examined the nuclear localisation properties of the NS5 protein of all four DENV types and found that there are major differences in the cellular localisation of the viral NS5 protein for the four DENV types.
The four types of DENV are genetically distinct. Although they can all cause dengue disease, little is known about how the genetic differences between them may translate into differences in virus replication and pathogenesis.
Previous studies by the team focusing on DENV-2, have shown that the viral NS5 protein is essential for DENV genome replication and is able to modulate the host immune response. As such, the NS5 protein is a key target for the development of anti-viral agents. Importantly, the team also showed that the DENV-2 NS5 protein accumulates in the nucleus during infection which is believed to effect host cell function.
Dr Davidson, Senior Lecturer in Virology, School of Cellular and Molecular Medicine at the University of Bristol, said: "The study shows for the first time that there may be significant differences in specific properties of the viral proteins for the four DENV types. This is important as it impacts on our understanding of viral replication and pathogenesis and the design of anti-viral therapies that are effective against all DENV types."
Present studies in the laboratory are focused on comprehensively comparing the effects of different DENV types on the host cell, using the state-of-the-art proteomics facilities at the University of Bristol.
###
Further information
Paper
The paper, entitled 'Serotype-specific Differences in Dengue Virus Non-structural Protein 5 Nuclear Localization' is published in the Journal of Biological Chemistry, Vol. 288, Issue 31, 22621-22635, August 2, 2013.
Holger Hannemann (University of Bristol); Po-Yu Sung (University of Bristol); Han-Chen Chiu (University of Bristol); Amjad Yousuf (University of Bristol and Taif University); Jim Bird (University of Bristol); Andrew D. Davidson (University of Bristol) and Siew Pheng Lim(Novartis Institute for Tropical Diseases).
Dengue
Dengue is a mosquito-borne infection found in tropical and sub-tropical regions around the world. In recent years, transmission has increased predominantly in urban and semi-urban areas and has become a major international public health concern.
Dengue is a mosquito-borne viral infection.
The infection causes flu-like illness, and occasionally develops into a potentially lethal complication called severe dengue.
The global incidence of dengue has grown dramatically in recent decades.
About half of the world's population is now at risk.
Dengue is found in tropical and sub-tropical climates worldwide, mostly in urban and semi-urban areas.
Severe dengue is a leading cause of serious illness and death among children in some Asian and Latin American countries.
There is no specific treatment for dengue/ severe dengue, but early detection and access to proper medical care lowers fatality rates below 1 per cent.
Dengue prevention and control solely depends on effective vector control measures.
Source: WHO
Notes to editors
For more information or to arrange an interview with Dr Andrew Davidson, please contact the University of Bristol Press Office, tel. +44 (0) 117 928 8086, tel mobile. +44 (0)7776 170238, email. Press-office@bristol.ac.uk
Paper
An advance copy of the paper is available to download from the below URL
https://fluff.bris.ac.uk/fluff/u3/ficmc/xBhVeusEDrKVQrVlbvJIZQGx5/
Issued by the Public Relations Office, Marketing & Communications Division, University of Bristol
New findings could influence the development of therapies to treat dengue disease
2013-08-02
ELSE PRESS RELEASES FROM THIS DATE:
Wired for change
2013-08-02
A study of gene expression led by scientists at the EMBL-European Bioinformatics Institute (EMBL-EBI) and the University of Cambridge has revealed the first steps of evolution in gene regulation in mice. Published in the journal Cell, the research has implications for the study of differences in gene regulation between people.
"We found an impressive amount of variation between these apparently very similar mice in terms of transcription-factor binding, which is an important indicator of gene-regulation activity," says Paul Flicek of EMBL-EBI. "Often you'll see a specific ...
Added benefit of lixisenatide is not proven
2013-08-02
Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy. No such added benefit ...
Apixaban in atrial fibrillation: Indications of considerable added benefit
2013-08-02
The clot-inhibiting drug apixaban (trade name: Eliquis) has been approved in Germany since November 2012 for the prevention of embolism and stroke in adults with non-valvular atrial fibrillation. In an early benefit assessment pursuant to the "Act on the Reform of the Market for Medicinal Products" (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) examined the added benefit of apixaban.
IQWiG found an indication of a considerable added benefit of apixaban for each of two patient groups: Patients who can also be treated with a vitamin K antagonist ...
Baby owls sleep like baby humans
2013-08-02
Researchers at the Max Planck Institute for Ornithology and the University of Lausanne have discovered that the sleeping patterns of baby birds are similar to that of baby mammals. What is more, the sleep of baby birds appears to change in the same way as it does in humans. Studying barn owls in the wild, the researchers discovered that this change in sleep is strongly correlated with the expression of a gene involved in producing dark, melanic feather spots, a trait known to covary with behavioral and physiological traits in adult owls. These findings raise the intriguing ...
Vandetanib in thyroid cancer: Added benefit not proven
2013-08-02
Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. In a new benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG).
There is a hint that pain occurs later or gets worse later in a part of the patients, the ones aged under 65 years.But because of the overall poor data on side effects, no ...
Decoding material fluxes in the tropical ocean
2013-08-02
August 2, 2013 / Kiel. How is vital oxygen supplied to the tropical ocean? For the first time, oceanographers at GEOMAR Helmholtz Centre for Ocean Research Kiel were able to make quantitative statements regarding this question. They showed that about one third of the oxygen supply in these areas is provided by turbulent processes, such as eddies or internal waves. The study, conducted in the framework of the Collaborative Research Center SFB 754 "Climate-Biogeochemistry Interactions in the Tropical Ocean", was just published in the international journal Biogeosciences.
In ...
Pollutants from incense smoke cause human lung-cell inflammation
2013-08-02
Burning incense, a popular cultural practice in Arabian Gulf countries and elsewhere, generates indoor air pollutants that may cause inflammation in human lung cells, say researchers in the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill.
"Hazard assessment of United Arab Emirates (UAE) incense smoke" appears in the August 2013 issue of Science of the Total Environment. Rebecca Cohen, master's student in environmental sciences and engineering (ESE); her adviser, Kenneth G. Sexton, now retired ESE research assistant professor; ...
Bio-inspired design may lead to more energy efficient windows
2013-08-02
TORONTO, ON – University of Toronto Engineering professor Ben Hatton is turning to nature to find a way to cut down on the energy leaks from windows.
In an article in Solar Energy Materials & Solar Cells, Hatton and his colleagues at Harvard University describe a novel process to cut down on heat loss during the winter and keep buildings cool during the summer. Their "bio-inspired approach to thermal control for cooling (or heating) building window surfaces" calls for attaching optically clear, flexible elastomer sheets, bonded to regular glass window panes. The elastomer ...
Why can't the snakes cross the road, secret lives of baby snakes and other questions
2013-08-02
Why can't the pine snakes cross the road? Hint: New Jersey traffic might have something to do with it.
Drexel University students will bring to light these and other findings about the plight, perils and peculiarities of the Northern Pine Snake in several presentations and posters at the Ecological Society of America annual meeting next week (ESA 2013), based on their research with Dr. Walt Bien's Laboratory of Pinelands Research in the New Jersey Pinelands.
Northern pine snakes are charismatic ambassadors for the Pinelands National Reserve, an ecologically important ...
Take your child's word for it on asthma, study finds
2013-08-02
SAN ANTONIO -- Children's perceptions of living with asthma may differ significantly from their caregivers' perceptions, which means both should be interviewed when they visit the doctor's office, a new study from UT Kids San Antonio and the Center for Airway Inflammation Research (cAIR) shows.
The study analyzed the agreement between 79 children and their caregivers on health-related quality-of-life questionnaires. The children ranged in age from 5 to 17. Fifty-three were classified as having acute asthma and 26 had refractory, or treatment-resistant, asthma.
Include ...